Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts

Mariangela Allocca, Gionata Fiorino, Camille Zallot, Federica Furfaro, Daniela Gilardi, Simona Radice, Silvio Danese, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticlepeer-review

Abstract

The first cases of COVID-19 infection were reported in December, 2019, in Wuhan, China. Italy (in particular Lombardy) and France (in particular Northeast) have been gravely hit. Both physicians and inflammatory bowel disease (IBD) patients are deeply concerned that immunosuppressants or biologics may increase the risk of COVID-19 infection. IOIBD has put in place an international registry, SECURE-IBD, for tracking all the cases with IBDs infected by COVID-19 (SECURE-IBD registry: http://www.covidibd.org). It will describe the outcomes of infected patients and the association between IBD-related medications and these outcomes.

Original languageEnglish
Pages (from-to)2134-2135
Number of pages2
JournalClinical Gastroenterology and Hepatology
Volume18
Issue number9
DOIs
Publication statusPublished - Aug 2020

Keywords

  • Betacoronavirus/isolation & purification
  • COVID-19
  • Coronavirus Infections/epidemiology
  • France/epidemiology
  • Humans
  • Immunocompromised Host
  • Incidence
  • Inflammatory Bowel Diseases/complications
  • Italy/epidemiology
  • Pandemics
  • Pneumonia, Viral/epidemiology
  • Registries/statistics & numerical data
  • SARS-CoV-2

Fingerprint Dive into the research topics of 'Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts'. Together they form a unique fingerprint.

Cite this